Trials / Completed
CompletedNCT02643901
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GW003 | single SC injection |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-10-10
- Completion
- 2016-10-10
- First posted
- 2015-12-31
- Last updated
- 2017-08-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02643901. Inclusion in this directory is not an endorsement.